Popular Articles

NICE Approves Use Of Lenalidomide In Patients With Multiple Myeloma Who Have Received Two Or More Previous Therapies
Around 2000 multiple myeloma sufferers in the UK could have their lives extended by around three months after a decision by The UK National Institute for Health and Clinical Excellence (NICE) to approve lenalidomide in those patients who have received two or more previous therapies-provided that the cost of cycles beyond the 26th cycle of treatment are met by the drug manufacturer. A summary of the NICE decision is published in a Special Report Online First and in the July edition of The Lancet Oncology.
generic viagra online
Elron Group Company Medingo Receives Formal FDA Clearance To Market Its Insulin Micropump In The United States
Elron Electronic Industries Ltd. (NASDAQ & TASE: ELRN) announced, that further to it previous announcement on July 28, 2009, Medingo Ltd., a group company held 92% by Elron and its subsidiary, RDC - Rafael Development Corporation Ltd., has received formal clearance from the Food and Drug Administration ("FDA"), to market its Solo™ MicroPump Insulin Delivery System in the United States.
News of the day
US Oncology Research Network Participates In Phase III Follow-up Study To BiPar's Investigational Cancer Drug BSI-201
US Oncology, Inc. today announced that US Oncology Research will participate in the BiPar Sciences" Phase III, Multi-center, Open-Label, Randomized Trial of Gemcitabine/Carboplatin (G/C), with or without BSI-201, in patients with Estrogen Receptor (ER), Progesterone Receptor (PR), and HER2-negative metastatic breast cancer.
Oncology

BMA Welcomes Call For Transparency On Cost Of NHS Management Consultants

The BMA on Thursday welcomed the Health Select Committee"s call for the government to gather central information on the cost to the NHS of private management consultants. In a speech on Wednesday, the chairman of the BMA"s Consultants Committee, Dr Jonathan Fielden, called for private management consultants to be "ditched" from the NHS. According to a recent estimate, the English NHS spent ÷£350 million on independent management consultants last year. Commenting on the Health Committee report, Dr Fielden says: "This is hundreds of millions of pounds of taxpayers" money that is yet to be shown to have benefited patient care. Particularly during an economic crisis, the public has a right to know how its money is being spent. "NHS staff already have widespread expertise and knowledge. The benefit of management consultants - steeped in the ethos of the private sector - must be questioned and needs to be justified." The British Medical Association


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):